

10. The method of claim **6**, wherein the benzonapthyridine TLR7 agonist is 2-(2-(4-(2-(5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethyl)-3-methylphenoxy)ethoxy)ethanol having the structure of



11. The method of claim **1**, wherein the hemorrhagic fever virus is a Filoviridae virus.

12. The method of claim **11**, wherein the Filoviridae virus is selected from the group consisting of Marburg virus and Ebola virus.

13. (canceled)

14. An immunogenic composition comprising: (a) benzonapthyridine compound, or salt, solvate, or derivative thereof, having the structure of:

Formula (II)



wherein:

R^3 is H, halogen, C_1-C_6alkyl, C_2-C_8alkene, C_2-C_8alkyne, C_1-C_6heteroalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aryl, heteroaryl, C_3-C_8cycloalkyl, and C_3-C_8heterocycloalkyl, wherein the C_1-C_6alkyl, C_1-C_6heteroalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_3-C_8cycloalkyl, or C_3-C_8heterocycloalkyl groups of R^3 are each optionally substituted with 1 to 3 substituents independently selected from halogen, —CN, —R^7, —OR^8, —$C(O)R^8$, —$OC(O)R^8$, —$C(O)OR^8$, —$N(R^9)_2$, —$C(O)N(R^9)_2$, —$S(O)_2R^8$, —$S(O)_2N(R^9)_2$ and —$NR^9S(O)_2R^8$;

R^4 and R^5 are each independently selected from H, halogen, —$C(O)OR^7$, —$C(O)R^7$, —$C(O)N(R^{11}R^{12})$, —$N(R^{11}R^{12})$, —$N(R^9)_2$, —$NHN(R^9)_2$, —SR^7, —$(CH_2)_nOR^7$, —$(CH_2)_nR^7$, -LR^8, -LR^{10}, —OLR^8, —OLR^{10}, C_1-C_6alkyl, C_1-C_6heteroalkyl, C_1-C_6haloalkyl, C_2-C_8alkene, C_2-C_8alkyne, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aryl, heteroaryl, C_3-C_8cycloalkyl, and C_3-C_8heterocycloalkyl, wherein the C_1-C_6alkyl, C_1-C_6heteroalkyl, C_1-C_6haloalkyl, C_2-C_8alkene, C_2-C_8alkyne, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aryl, heteroaryl, C_3-C_8cycloalkyl, and C_3-C_8heterocycloalkyl groups of R^4 and R^5 are each optionally substituted with 1 to 3 substituents independently selected from halogen, —CN, —NO_2, —R^7, —OR^8, —$C(O)R^8$, —$OC(O)R^8$, —$C(O)OR^8$, —$N(R^9)_2$, —$P(O)(OR^8)_2$, —$OP(O)(OR^8)_2$, —$P(O)(OR^{10})_2$, —$OP(O)(OR^{10})_2$, —$C(O)N(R^9)_2$, —$S(O)_2R^8$, —$S(O)R^8$, —$S(O)_2N(R^9)_2$, and —$NR^9S(O)_2R^8$;

or R^3 and R^4, or R^4 and R^5, when present on adjacent ring atoms, can optionally be linked together to form a 5-6 membered ring, wherein the 5-6 membered ring is optionally substituted with R^7;

each L is independently selected from a bond, —$(O(CH_2)_m)_t$—, C_1-C_6alkyl, C_2-C_6alkenylene and C_2-C_6alkynylene, wherein the C_1-C_6alkyl, C_2-C_6alkenylene and C_2-C_6alkynylene of L are each optionally substituted with 1 to 4 substituents independently selected from halogen, —R^8, —OR^8, —$N(R^9)_2$, —$P(O)(OR^8)_2$, —$OP(O)(OR^8)_2$, —$P(O)(OR^{10})_2$, and —$OP(O)(OR^{10})_2$;

R^7 is selected from H, C_1-C_6alkyl, aryl, heteroaryl, C_3-C_8cycloalkyl, C_1-C_6heteroalkyl, C_1-C_6haloalkyl, C_2-C_8alkene, C_2-C_8alkyne, C_1-C_6alkoxy, C_1-C_6haloalkoxy, and C_3-C_8heterocycloalkyl, wherein the C_1-C_6alkyl, aryl, heteroaryl, C_3-C_8cycloalkyl, C_1-C_6heteroalkyl, C_1-C_6haloalkyl, C_2-C_8alkene, C_2-C_8alkyne, C_1-C_6alkoxy, C_1-C_6haloalkoxy, and C_3-C_8heterocycloalkyl groups of R^7 are each optionally substituted with 1 to 3 R^{13} groups, and each R^{13} is independently selected from halogen, —CN, -LR^9, -LOR^9, —OLR^9, -LR^{10}, -LOR^{10}, —OLR^{10}, -LR^8, -LOR^8, —OLR^8, -LSR^8, -LSR^{10}, -$LC(O)R^8$, —$OLC(O)R^8$, -$LC(O)OR^8$, -$LC(O)R^{10}$, -$LOC(O)OR^8$, -$LC(O)NR^9R^{11}$, -$LC(O)NR^9R^8$, -$LN(R^9)_2$, -LNR^9R^8, -LNR^9R^{10}, -$LC(O)N(R^9)_2$, -$LS(O)_2R^8$, -$LS(O)R^8$, -$LC(O)NR^8OH$, -$LNR^9C(O)R^8$, -$LNR^9C(O)OR^8$, -$LS(O)_2N(R^9)_2$, —$OLS(O)_2N(R^9)_2$, -$LNR^9S(O)_2R^8$, -$LC(O)NR^9LN(R^9)_2$, -$LP(O)(OR^8)_2$, -$LOP(O)(OR^8)_2$, -$LP(O)(OR^{10})_2$ and —$OLP(O)(OR^{10})_2$;

each R^8 is independently selected from H, —$CH(R^{10})_2$, C_1-C_8alkyl, C_2-C_8alkene, C_2-C_8alkyne, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6heteroalkyl, C_3-C_8cycloalkyl, C_2-C_8heterocycloalkyl, C_1-C_6hydroxyalkyl and C_1-C_6haloalkoxy, wherein the C_1-C_8alkyl, C_2-C_8alkene, C_2-C_8alkyne, C_1-C_6heteroalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, C_2-C_8heterocycloalkyl, C_1-C_6hydroxyalkyl and C_1-C_6haloalkoxy groups of R^8 are each optionally substituted with 1 to 3 substituents independently selected from —CN, R^{11}, —OR^{11}, —SR^{11}, —$C(O)R^{11}$, —$OC(O)R^{11}$, —$C(O)N(R^9)_2$, —$C(O)OR^{11}$, —$NR^9C(O)R^{11}$, —NR^9R^{10}, —$NR^{11}R^{12}$, —$N(R^9)_2$, —OR^9, —OR^{10}, —$C(O)NR^{11}R^{12}$, —$C(O)NR^{11}R^{12}$, —$C(O)NR^{11}OH$, —$S(O)_2R^{11}$, —$S(O)R^{11}$, —$S(O)_2NR^{11}R^{12}$, —$NR^{11}S(O)_2R^{11}$, —$P(O)(OR^{11})_2$, and —$OP(O)(OR^{11})_2$;

each R^9 is independently selected from H, —$C(O)R^8$, —$C(O)OR^8$, —$C(O)R^{10}$, —$C(O)OR^{10}$, —$S(O)_2R^{10}$, —C_1-C_6 alkyl, C_1-C_6 heteroalkyl and C_3-C_6 cycloalkyl,